2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Monday, November 11, 2019

9:00AM-11:00AM: Abstract Number: 1666

Maintenance Treatment in ANCA Associated Vasculitis in Real World Clinical Practice – Burden of Disease, Use of Glucocorticoids and Impact on Patient Functional Status Remain Major Problems

Vasculitis – ANCA-Associated Poster II

9:00AM-11:00AM: Abstract Number: 1677

Management of Severe Renal Disease in Anti-Neutrophil-Cytoplasmic-Antibodies Associated Vasculitis: Role of Rituximab and Plasma Exchange?

Vasculitis – ANCA-Associated Poster II

9:00AM-11:00AM: Abstract Number: 1265

Mandibular Involvement in SAPHO Syndrome: A Single-center Retrospective Study of 26 Patients

Miscellaneous Rheumatic & Inflammatory Disease Poster II: Autoinflammation Related Diseases & Therapies

9:00AM-11:00AM: Abstract Number: 1033

Mass Cytometric Immunophenotyping Highlights a Dysregulated T cell-B Cell Axis in Patients with New-onset Lupus

SLE – Etiology & Pathogenesis Poster I

9:00AM-11:00AM: Abstract Number: 1077

Mediation of Adverse Pregnancy Outcomes in Autoimmune Conditions by Pregnancy Complications

Epidemiology & Public Health Poster II: Spondyloarthritis & Connective Tissue Disease

9:00AM-11:00AM: Abstract Number: 1134

Medicaid Spending (2013-2017) on Disease Modifying Agents Commonly Used in Rheumatoid Arthritis

Health Services Research Poster II – ACR/ARP

9:00AM-11:00AM: Abstract Number: 1133

Medicare Spending (2012-2017) on Disease Modifying Agents Commonly Used in Rheumatoid Arthritis

Health Services Research Poster II – ACR/ARP

9:00AM-11:00AM: Abstract Number: 1007

Memory ex-Th17 Cells Contribute to Synovial Inflammation in Spondyloarthritis

Spondyloarthritis Including Psoriatic Arthritis – Basic Science Poster

9:00AM-11:00AM: Abstract Number: 961

Microenvironment in Systemic Sclerosis Provides a Protective Niche for Tissue-resident B Cells During B Cell Depletion Therapy with Anti-CD20 Antibody

B Cell Biology & Targets In Autoimmune & Inflammatory Disease Poster

9:00AM-11:00AM: Abstract Number: 966

Minimal Residual Autoimmunity After Rituximab in ANCA-associated Vasculitis Patients

B Cell Biology & Targets In Autoimmune & Inflammatory Disease Poster

9:00AM-11:00AM: Abstract Number: 1460

Minor Salivary Gland Biopsy and Dry Ocular Tests to Detect Occult Sjögren Syndrome in Patients with Interstitial Pneumonia with Autoimmune Features

Sjögrenʼs Syndrome – Basic & Clinical Science Poster II

9:00AM-11:00AM: Abstract Number: 1722

Mixed Cryoglobulin Immune Complex Proteomics: Analysis by Mass Spectroscopy

Vasculitis – Non-ANCA-Associated & Related Disorders Poster III: Behçet’s Disease & Other Vasculitides

9:00AM-11:00AM: Abstract Number: 1723

Mixed Cryoglobulinaemia Since the Advent of New Direct-acting Antivirals for Hepatitis C Infection: Clinical Characteristics, Etiologies and Biological Features in 679 Patients

Vasculitis – Non-ANCA-Associated & Related Disorders Poster III: Behçet’s Disease & Other Vasculitides

9:00AM-11:00AM: Abstract Number: 1108

Mobile Apps in Rheumatology: Review and Analysis Using the Mobile App Rating Scale (MARS)

Health Services Research Poster II – ACR/ARP

9:00AM-11:00AM: Abstract Number: 1039

Molecular Profiling Identifies Immunologic Subgroups and Informs Mechanism of Action of Baricitinib in SLE

SLE – Etiology & Pathogenesis Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].